Anthem Biosciences' Q1FY27 revenue dropped 22.6% YoY to ₹418.2 Cr, with profit after tax falling 11.7% to ₹119.9 Cr.

Both CRDMO and Specialty Ingredients segments saw revenue declines.

Despite this, the company maintained strong margins, with EBITDA at 39.6% and PAT at 27.1%, showing YoY improvement due to cost discipline.

Management attributes the Q1 performance to timing shifts in customer deliveries, emphasizing strong underlying demand.

They anticipate a stronger second half with a higher concentration of scheduled deliveries.

The focus remains on cost efficiencies, yield optimization, and employee productivity to sustain industry-leading margins.

No new product launches or capacity expansions were highlighted.

The company holds a robust net cash position of ₹1719.7 Cr.